Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Dalteparin · Fragmin

Small molecule · Modulator of coagulation factor Xa (F10) · developed by Pfizer

Approved FDA, Dec 1994
1 Registered trials

What is Dalteparin?

Dalteparin is a low molecular weight heparin that enhances antithrombin's inhibition of coagulation factor Xa and thrombin, with preferential action on factor Xa. It is studied in deep venous thrombosis and pulmonary embolism.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Fragmin
Drug type
Small molecule
Targets
antithrombin (SERPINC1) (binding partner it blocks), coagulation factor Xa (F10), thrombin (F2) (secondary target)
Mechanism
Modulator of coagulation factor Xa (F10)
Pathways
coagulation cascade, antithrombin-mediated inhibition of factor Xa and thrombin
Therapy area
Cardiovascular
Developer
Pfizer
In trials of
ASPE
FDA status
Approved as Fragmin (December 22, 1994), NDA020287 · FDA label
UNII
S79O08V79F

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 30, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01828697 Phase 4 Deep Venous Thrombosis Completed ASPE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Deep Venous ThrombosisPulmonary Embolism

Other drugs acting on F10

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.